Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792314 | 0.84 | SLC6A9 (0.44) | AKR1C3SLC6A9SMN1; SMN2KDM4ESLC6A5 | |
| SCHEMBL14731319 | 0.79 | AKR1C3 (0.51) | AKR1C3SMN1; SMN2KDM4EMAPTMEN1 | |
| SCHEMBL13211362 | 0.79 | ALDH1A1 (0.50) | AKR1C3SLC6A9SMN1; SMN2KDM4ESLC6A5 | |
| SCHEMBL11554889 | 0.78 | KDM4E (0.67) | AKR1C3SLC6A9SMN1; SMN2KDM4EMAPT | |
| SCHEMBL12560142 | 0.78 | SLC6A9 (0.62) | SLC6A9SMN1; SMN2ALDH1A1 | |
| SCHEMBL1811174 | 0.78 | SMN1; SMN2 (0.74) | AKR1C3SLC6A9SMN1; SMN2KDM4ESLC6A5 | |
| SCHEMBL1475834 | 0.78 | ALDH1A1 (0.61) | AKR1C3SMN1; SMN2KDM4EMAPTMEN1 | |
| SCHEMBL18394710 | 0.75 | SMN1; SMN2 (0.59) | AKR1C3SLC6A9SMN1; SMN2KDM4ESLC6A5 | |
| SCHEMBL19496857 | 0.75 | AKR1C3 (0.52) | AKR1C3SMN1; SMN2SLC6A5MAPTMEN1 | |
| SCHEMBL188672 | 0.75 | MAPT (0.61) | AKR1C3SMN1; SMN2KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | AKR1C3 2216/4885SLC6A9 2046/4885SMN1; SMN2 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.